Drug therapy of attention deficit hyperactivity disorder: current trends

Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the m...

Full description

Saved in:
Bibliographic Details
Published in:Mens sana monographs 2012-01, Vol.10 (1), p.45-69
Main Authors: De Sousa, Avinash, Kalra, Gurvinder
Format: Article
Language:English
Subjects:
Attention deficit disorder
Attention-deficit hyperactivity disorder
Children & youth
Drug delivery systems
Drug therapy
Drug wholesalers
Drugs
Hyperactivity
Medical treatment
Review
Transdermal medication
Vehicles
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4031-da034f5cfebbd9b23a275d81d185daa435b34bd7fd728d14e58329fedb4a1c1e3
cites
container_end_page 69
container_issue 1
container_start_page 45
container_title Mens sana monographs
container_volume 10
creator De Sousa, Avinash
Kalra, Gurvinder
description Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the mainstay of ADHD treatment for decades with evidence supporting their use. However, recent years have seen emergence of newer drugs and drug delivery systems, like osmotic release oral systems and transdermal patches, to mention a few. The use of nonstimulant drugs like atomoxetine and various other drugs, such as α-agonists, and a few antidepressants, being used in an off-label manner, have added to the pharmacotherapy of ADHD. This review discusses current trends in drug therapy of ADHD and highlights the promise pharmacogenomics may hold in the future.
doi_str_mv 10.4103/0973-1229.87261
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3353606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A289868580</galeid><sourcerecordid>A289868580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4031-da034f5cfebbd9b23a275d81d185daa435b34bd7fd728d14e58329fedb4a1c1e3</originalsourceid><addsrcrecordid>eNptkU1LJDEQhoOs6Ozo2dvSsJe99Jikku70HhbE_VAQvOg5pPMxE-npzCZpYf69mVUHXSSQQNVTb6XqReiM4AUjGM5x10JNKO0WoqUNOUAz0nWiZpiwT2i2zx6jzyk9YNyAwOIIHVPacAaCztDVzzgtq7yyUW22VXCVytmO2YexMtZ57XO12m5KVmf_6PO2Mj6FaGz8XukpxoJWudwmnaBDp4ZkT1_eObr__evu8qq-uf1zfXlxU2uGgdRGYWCOa2f73nQ9BUVbbgQxRHCjFAPeA-tN60xLhSHMcgG0c9b0TBFNLMzRj2fdzdSvrdHlB1ENchP9WsWtDMrL95nRr-QyPEoADk3ZwBx9exGI4e9kU5Zrn7QdBjXaMCVJMBHAO1waz9HX_9CHMMWxjFcoioFzEG-opRqs9KMLpa_eicoLKjrRCC5woRYfUOUYu_Y6jGXZJf6u4Py5QMeQUrRuPyPBcme-3Nkrd_bKf-aXii9vV7PnX92GJ_ggqcI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020355388</pqid></control><display><type>article</type><title>Drug therapy of attention deficit hyperactivity disorder: current trends</title><source>PubMed Central</source><creator>De Sousa, Avinash ; Kalra, Gurvinder</creator><creatorcontrib>De Sousa, Avinash ; Kalra, Gurvinder</creatorcontrib><description>Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the mainstay of ADHD treatment for decades with evidence supporting their use. However, recent years have seen emergence of newer drugs and drug delivery systems, like osmotic release oral systems and transdermal patches, to mention a few. The use of nonstimulant drugs like atomoxetine and various other drugs, such as α-agonists, and a few antidepressants, being used in an off-label manner, have added to the pharmacotherapy of ADHD. This review discusses current trends in drug therapy of ADHD and highlights the promise pharmacogenomics may hold in the future.</description><identifier>ISSN: 0973-1229</identifier><identifier>EISSN: 1998-4014</identifier><identifier>DOI: 10.4103/0973-1229.87261</identifier><identifier>PMID: 22654382</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Attention deficit disorder ; Attention-deficit hyperactivity disorder ; Children &amp; youth ; Drug delivery systems ; Drug therapy ; Drug wholesalers ; Drugs ; Hyperactivity ; Medical treatment ; Review ; Transdermal medication ; Vehicles</subject><ispartof>Mens sana monographs, 2012-01, Vol.10 (1), p.45-69</ispartof><rights>COPYRIGHT 2012 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications &amp; Media Pvt Ltd Jan 2012</rights><rights>Copyright: © Mens Sana Monographs 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4031-da034f5cfebbd9b23a275d81d185daa435b34bd7fd728d14e58329fedb4a1c1e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353606/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353606/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,4043,27956,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22654382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Sousa, Avinash</creatorcontrib><creatorcontrib>Kalra, Gurvinder</creatorcontrib><title>Drug therapy of attention deficit hyperactivity disorder: current trends</title><title>Mens sana monographs</title><addtitle>Mens Sana Monogr</addtitle><description>Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the mainstay of ADHD treatment for decades with evidence supporting their use. However, recent years have seen emergence of newer drugs and drug delivery systems, like osmotic release oral systems and transdermal patches, to mention a few. The use of nonstimulant drugs like atomoxetine and various other drugs, such as α-agonists, and a few antidepressants, being used in an off-label manner, have added to the pharmacotherapy of ADHD. This review discusses current trends in drug therapy of ADHD and highlights the promise pharmacogenomics may hold in the future.</description><subject>Attention deficit disorder</subject><subject>Attention-deficit hyperactivity disorder</subject><subject>Children &amp; youth</subject><subject>Drug delivery systems</subject><subject>Drug therapy</subject><subject>Drug wholesalers</subject><subject>Drugs</subject><subject>Hyperactivity</subject><subject>Medical treatment</subject><subject>Review</subject><subject>Transdermal medication</subject><subject>Vehicles</subject><issn>0973-1229</issn><issn>1998-4014</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkU1LJDEQhoOs6Ozo2dvSsJe99Jikku70HhbE_VAQvOg5pPMxE-npzCZpYf69mVUHXSSQQNVTb6XqReiM4AUjGM5x10JNKO0WoqUNOUAz0nWiZpiwT2i2zx6jzyk9YNyAwOIIHVPacAaCztDVzzgtq7yyUW22VXCVytmO2YexMtZ57XO12m5KVmf_6PO2Mj6FaGz8XukpxoJWudwmnaBDp4ZkT1_eObr__evu8qq-uf1zfXlxU2uGgdRGYWCOa2f73nQ9BUVbbgQxRHCjFAPeA-tN60xLhSHMcgG0c9b0TBFNLMzRj2fdzdSvrdHlB1ENchP9WsWtDMrL95nRr-QyPEoADk3ZwBx9exGI4e9kU5Zrn7QdBjXaMCVJMBHAO1waz9HX_9CHMMWxjFcoioFzEG-opRqs9KMLpa_eicoLKjrRCC5woRYfUOUYu_Y6jGXZJf6u4Py5QMeQUrRuPyPBcme-3Nkrd_bKf-aXii9vV7PnX92GJ_ggqcI</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>De Sousa, Avinash</creator><creator>Kalra, Gurvinder</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201201</creationdate><title>Drug therapy of attention deficit hyperactivity disorder: current trends</title><author>De Sousa, Avinash ; Kalra, Gurvinder</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4031-da034f5cfebbd9b23a275d81d185daa435b34bd7fd728d14e58329fedb4a1c1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Attention deficit disorder</topic><topic>Attention-deficit hyperactivity disorder</topic><topic>Children &amp; youth</topic><topic>Drug delivery systems</topic><topic>Drug therapy</topic><topic>Drug wholesalers</topic><topic>Drugs</topic><topic>Hyperactivity</topic><topic>Medical treatment</topic><topic>Review</topic><topic>Transdermal medication</topic><topic>Vehicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Sousa, Avinash</creatorcontrib><creatorcontrib>Kalra, Gurvinder</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Mens sana monographs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Sousa, Avinash</au><au>Kalra, Gurvinder</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug therapy of attention deficit hyperactivity disorder: current trends</atitle><jtitle>Mens sana monographs</jtitle><addtitle>Mens Sana Monogr</addtitle><date>2012-01</date><risdate>2012</risdate><volume>10</volume><issue>1</issue><spage>45</spage><epage>69</epage><pages>45-69</pages><issn>0973-1229</issn><eissn>1998-4014</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the mainstay of ADHD treatment for decades with evidence supporting their use. However, recent years have seen emergence of newer drugs and drug delivery systems, like osmotic release oral systems and transdermal patches, to mention a few. The use of nonstimulant drugs like atomoxetine and various other drugs, such as α-agonists, and a few antidepressants, being used in an off-label manner, have added to the pharmacotherapy of ADHD. This review discusses current trends in drug therapy of ADHD and highlights the promise pharmacogenomics may hold in the future.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>22654382</pmid><doi>10.4103/0973-1229.87261</doi><tpages>25</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-1229
ispartof Mens sana monographs, 2012-01, Vol.10 (1), p.45-69
issn 0973-1229
1998-4014
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3353606
source PubMed Central
subjects Attention deficit disorder
Attention-deficit hyperactivity disorder
Children & youth
Drug delivery systems
Drug therapy
Drug wholesalers
Drugs
Hyperactivity
Medical treatment
Review
Transdermal medication
Vehicles
title Drug therapy of attention deficit hyperactivity disorder: current trends
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T04%3A55%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20therapy%20of%20attention%20deficit%20hyperactivity%20disorder:%20current%20trends&rft.jtitle=Mens%20sana%20monographs&rft.au=De%20Sousa,%20Avinash&rft.date=2012-01&rft.volume=10&rft.issue=1&rft.spage=45&rft.epage=69&rft.pages=45-69&rft.issn=0973-1229&rft.eissn=1998-4014&rft_id=info:doi/10.4103/0973-1229.87261&rft_dat=%3Cgale_pubme%3EA289868580%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4031-da034f5cfebbd9b23a275d81d185daa435b34bd7fd728d14e58329fedb4a1c1e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1020355388&rft_id=info:pmid/22654382&rft_galeid=A289868580&rfr_iscdi=true